Immunotherapy is an exciting, cutting-edge treatment that has given some patients with cancers like lymphoma and melanoma a more promising outlook. It is a simple yet effective form of cancer therapy that is helping transform cancer care at Cochise Oncology.
Immunotherapy is a precision medicine tool that provides durable outcomes in advanced cancers. But what is the success rate of immunotherapy?
Cancer immunotherapy or immuno-oncology is an innovative treatment that harnesses the body’s immune system to detect and attack cancer cells. It boosts the natural defenses of the immune system so it can identify cancer cells more efficiently and fight against them.
There are different types of immunotherapies including, CAR T-cell Therapy, cancer vaccines, and immunomodulators. Immunotherapy is often combined with other cancer treatments to achieve the best outcomes.
Immunotherapy is a more targeted treatment than conventional therapies such as radiation and chemotherapy. Because of this, it avoids the potential damage to healthy tissue commonly seen in these therapies.
Simply fill out the form on this page to request an appointment and one of our knowledgable team members will reach out to you. Or call our Sierra Vista oncology center to schedule directly at (520) 803-6644.
Immunotherapy is helping improve outcomes for people with several types of cancer that typically have a poor diagnosis including advanced bladder, kidney, and lung cancers.
The average response rate of cancer patients to immunotherapy drugs is between 20 to 50%. The response rate depends on the type of cancer being treated. However, oncologists believe that durable responses could increase as immunotherapy research advances, and researchers gain new insights into how the immune system and cancer cells interact.
Cancer signals a breakdown in the immune system, which means the immune cells cannot defend against invaders. Immuno-oncology boosts the efficiency of the immune system, allowing it to fight the growing cancer cells.
A study conducted by UCLA researchers involving patients with non-small cell lung cancer (NSCLC) found that the immunotherapy drug pembrolizumab increased the average 5-year survival rate of these patients from 5.5% to 15%.
While immunotherapy is not beneficial for all types of cancers, the success achieved indicates that it does have a positive impact on cancer patients and saves lives.
Immunotherapy clinical trials are ongoing. Researchers at the Johns Hopkins Kimmel Cancer Center are conducting studies into novel immunotherapies known as anti-PD-1 and anti-PD-L-1. These therapies have the potential to increase both clinical responses and survival rates.
*Individual Results May Vary
At Cochise Oncology, we know optimal cancer treatment places the patient first – and our patients experience this every day. Read what our satisfied patients are saying about their experiences at Cochise Oncology.
Would you like to learn more about the success rate of immunotherapy? Reach out to Cochise Oncology at (520) 803-6644 or fill out the consultation form on this page. We look forward to meeting you!
Fill out the form below to request an appointment at our state-of-the-art oncology center in Sierra Vista, AZ.
© Copyright 2024 Cochise Oncology | Website Design by ADvance Media
